Browse grants

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4. Distinctive Features: · Clinical trials are required. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

National Institutes of Health · Up to $500K

This funding opportunity aims to support the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Both structural and functional aspects, including visualizing dynamic elements are important to development of new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Ultimately, research supported in response to this RFA is to encourage technologies that allow, for example, structures such as hair cells, otoliths, membranes, ions, and vasculature to be viewed in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multi-disciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans and intermediate studies in animals, but not non-mammalian species, may be proposed to develop or advance the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans.

National Institutes of Health · Up to $500K

This funding opportunity aims to support high risk clinical trials for the development of in vivo high-resolution structural and functional imaging technologies for the living human inner ear. Proposed projects should focus on improving the resolution of current imaging techniques or developing new imaging techniques that can visualize inner ear structures in vivo with significantly greater detail and accuracy than currently possible. Structural and functional aspects, including visualizing dynamic elements, are important to developing new and improved techniques. Projects may also focus on developing new imaging probes or contrast agents that can enhance visualization of the inner ear structures. Research supported in response to this RFA is expected to significantly advance the ability to visualize auditory and vestibular components, such as hair cells, otoliths, membranes, ions, and vasculature, in detail in awake patients in a clinical setting using non-invasive techniques. To achieve this goal, a multidisciplinary team approach that takes advantage of the expertise of each team member is highly encouraged. Studies in humans must be proposed to develop,advance, or test the needed technology. Any intermediate studies must articulate a clear path of the proposed methodology to application in awake humans or define the limitations and the usefulness in anesthetized humans.

U.S. National Science Foundation · $475K–$7.5M

With a focus on two-year Institutions of Higher Education (IHEs), the Advanced Technological Education (ATE) program supports the education of technicians for the high-technology fields that drive our nation's economy. The program involves partnerships between academic institutions (grades 7-12, IHEs), industry, and economic development agencies to promote improvement in the education of science and engineering technicians. It is strongly recommended that projects be faculty-led and required that courses and programs are credit-bearing, although materials developed may also be used for incumbent worker education. Materials may also be adapted and implemented as credit-bearing courses. The ATE program supports curriculum development; professional development of college faculty and secondary school teachers; career pathway development for both students and incumbent workers; and other activities including applied research projects that advance the knowledge base related to technician education. The ATE program encourages partnerships with other entities that may impact technician education. For example, with the National Institute of Standards and Technology (NIST) Manufacturing Extension Partnerships (MEPs) ( http://www.nist.gov/mep/index.cfm ) as applicable to support technician education programs and the industries they serve; and Manufacturing USA Institutes( https://manufacturing.gov/ ) addressing workforce development issues. The ATE program encourages proposals from Minority Serving Institutions as well as other institutions that support the recruitment, retention, and completion (certificate, degree, program)of the full spectrum of diverse talent that society has to offer, which includes underrepresented and underserved communities, in STEM technician education programs that award associate degrees.

National Institutes of Health · Amount varies

This notice of funding opportunity (NOFO) invites applications from eligible organizations to establish a Data Coordination and Integration Center (DCIC) for the NIH HEAL Initiative. This Center will support the coordination and integration of data from both the HEAL INTERACT program and progressively facilitate broader integration of related musculoskeletal datasets and programs. The Data Coordination and Integration Center will lead efforts for managing and integrating complex pain-associated data types and information from the INTERACT Consortium and progressively related datasets. It will also establish a web-accessible information system and disseminate datasets that can facilitate hypothesis generation and be widely used throughout the research community.

U.S. National Science Foundation · $500K–$2.5M

The EDU Core Research (ECR) program offers this ECR:Core solicitation and invites proposals for fundamental research (curiosity-driven basic research and use-inspired basic research) that contributes to the general, explanatory knowledge that underlies STEM education in one or more of the three broadly conceived Research Areas: Research onSTEM Learning and Learning Environments, Research on Broadening Participation in STEM fields, andResearch on STEM Workforce Development. Within this framework, the ECR program supports a wide range of fundamental STEM education research activities, aimed at learners of all groups and ages in formal and informal settings. Fundamental researchgenerates knowledge and understanding with the potential for broad relevance. The potential implications of ECR fundamental research for improving STEM education practice may be indirect and long-term rather than direct and immediate. Moreover, whether they include basic or use-inspired basic research, all successful ECR:Core proposals focus on the advancement or refinement of foundational knowledge for STEM education. The amount of funding and duration requested in proposals submitted to the ECR:Core solicitation should align with the maturity of the proposed work and the size and scope of the empirical effort. The solicitation has three levels of funding with a range of budget sizes, and proposals may request a duration of 3 to 5 years for any level: (1)Level I proposals may request up to $500,000; (2)Level II proposals may request up to $1,500,000; (3)Level III proposalsmay request up to $2,500,000. All proposals should justify the level of funding and duration in the project description.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The Ovarian Cancer Pilot Award supports research that expands or modifies current thinking about and/or approaches in ovarian cancer, exploring innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. Distinctive Features: Innovation is key. Research projects that demonstrate exceptional scientific merit but lack innovation do not meet the intent of the mechanism. Preliminary data are not required but are allowed for this mechanism. This mechanism includes a blinded pre-application component. Pre-applications to this funding opportunity will undergo a blinded pre-application screening. While preparing your pre-application, do not include any material that may identify the PI, a collaborator, or the organization of the PI or collaborator.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the OCA is to conduct innovative and impactful ovarian cancer research while developing successful, highly productive ovarian cancer researchers in a collaborative research and career development environment. Distinctive Features: The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs), their Designated Mentors, and an Academy Dean and Assistant Dean. The OCA-ECI Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, the Dean and Assistant Dean) as well as with the advocacy community.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: Created in FY23, the Ovarian Cancer Clinical Trial Academy (OCCTA) supports the next generation of Early-Career Investigators (ECIs) in clinical trial research to produce effective treatments and cures for ovarian cancer. The OCCTA, through its Leadership, provides for professional and leadership development of the ECIs to include skills and competencies needed to execute clinical trials, providing intensive mentoring, national networking, collaborations, and a peer group for junior clinical trialists. The OCCTA will bring together established investigators (the Academy Dean and Assistant Dean), established Career Guides (mentors), and a group of ECIs/Scholars to conduct successful, highly productive clinical trials in ovarian cancer. Distinctive Features: Research funded under this FY26 funding opportunity will support translational research and small-scale, early-phase clinical trials in ovarian cancer. Preliminary data are required, however, these data do not necessarily need to be derived from the ovarian cancer research field. The ECI must be within 12 years of their last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent at the time of full application submission deadline. The ECI must commit no less than 25% effort to this award and/or OCCTA activities for the first two years. The Designated Mentor must be a clinical trialist with a strong record of mentoring and training early-career investigators.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Distinctive Features: Application must contain strong research plan with sound scientific rational and logical reasoning. Preliminary data are required. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. Partnering Principal Investigator (PI) Option: The Partnering PI Option is structured so that two investigators, each of whom will be designated as a PI, will work synergistically on a single project. The results of this partnering project should significantly advance the research beyond what would be possible through individual efforts.

National Institutes of Health · Amount varies

This Notice of Funding Opportunity (NOFO) invites exploratory grant applications, hereafter referred to as the Novel Experiential Technologies Assisting Individual learning Hubs or NExT AI Hubs (formerly Learning Disabilities Innovation Hubs), to address the impact of Artificial Intelligence (AI) technologies on developmental outcomes in children diagnosed with or at risk for developing a specific learning disability (SLD) impacting reading, writing, and mathematics. NExT AI Hubs include a single Research Project and a Leadership Core that support the goals and aims of the Hub. This NOFO seeks to serve as a catalyst to 1) speed the maturation of nascent/novel, high-impact, high-risk research that advances understanding of the role AI technology plays in supporting, improving, or limiting the learning, cognitive, and socio-emotional needs of children at risk for or diagnosed with SLDs, 2) build an evidence base for the SLD community to inform policy or practice, and 3) provide project-embedded, career-enhancing research and professional development opportunities to support the next generation of transdisciplinary SLD scientists. This initiative provides opportunities to support planning and building a body of research and corresponding intellectual infrastructure to enable NExT AI investigators to compete for large research and program project opportunities in the future.This NOFO aims to integrate research topics that are of relevance to various research programs at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and align with the NICHD Strategic Plan. The NOFO intends to build cross-programmatic, transdisciplinary and cross-cutting scientific research, and critically nurture the development of early career investigators capable of conducting this research.

National Institutes of Health · Up to $800K

This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. The purpose of this NOFO is to seek applications in a limited competition for the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers (IDDRCs). This NOFO invites applications to undergo peer review for research center grants designed to advance the diagnosis, prevention, treatment, and amelioration of intellectual and developmental disabilities (IDD) and is limited to IDDRCs funded under RFA-HD-20-016 or RFA-HD-21-009. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.This NOFO seeks applications from institutions that meet the qualifications for a multidisciplinary program of IDD research that will include: 1) 3-4 total Cores that facilitate interdisciplinary and translational research in IDD and its dissemination, and that support IDD-related projects funded by other sources; and 2) at least two and no more than three specific research projects related to one of several areas identified as areas of research need in IDD. Collaborative investigations combining expertise in translational science, biomarker assessment, outcome measure development, tool validation, bioinformatics, and therapeutic development will be encouraged. Funds for the majority of outside research projects using these core facilities come from independent sources including Federal, State, and private organizations. In addition, the Center should include plans for outreach, engagement, and dissemination to the community, including persons with lived experience (PWLE) of disabilities. The duration of these Centers will be 3 years in total.

National Institutes of Health · Amount varies

The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human sensory and communication disorders. For this announcement, Clinical Research is defined as research involving individuals with a sensory and/or communication disorder, or data/tissues from individuals with a sensory and/or communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Although the intent is that all the research will involve individuals with sensory and/or communication disorders or data/tissues from individuals with sensory and/or communication disorders, when the clinical research goal(s) warrant(s) limited departures from this intent, alternatives (e.g., non-human research, human subjects without a sensory or communication disorder, human at risk for a sensory and/or communication disorder) are possible with appropriate and strong scientific justification and in consultation with NIDCD staff. Applications may propose a low-risk clinical trial but are not required to (optional).Non-responsive applications will not be reviewed. Prospective applicants are strongly encouraged to read this funding opportunity carefully and communicate with the scientific/research contact listed at the end of this award as early as possible to discuss their application plans.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public. Distinctive Features: The proposed project should demonstrate creative thinking and innovation. • Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award. • Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale. • New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS). Distinctive Features: • Applications must include preliminary data to support feasibility of the study. • Projects must have strong potential to result in a near-term impact in cancer. • The funding mechanism allows clinical trials. • This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

National Institutes of Health · Amount varies

This notice of funding opportunity (NOFO) invites applications designed to examine the efficacy and clinical effectiveness of multimodality digital health technology approaches to the remote management of diabetes.

Defense Health Agency Contracting Activity - DHACA · Amount varies

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Focused Pilot Award supports the exploration and development of impactful and innovative concepts under a patient-centered focus area of pancreatic cancer research that could ultimately lead to major advancements that will have a profound effect on patients’ overall quality of life. The research this award supports should strive to produce robust preliminary data that can serve as a foundation for future clinical or real-world research application. Distinctive Features: This award mechanism allows, but does not require, preliminary data. Applications can support clinical research studies; however, this mechanism does not allow clinical trials. Preclinical animal studies do not meet the intent of this mechanism.